GenoSolutions offers a very comprehensive estrogenomic test.

This test:

• Evaluates polymorphisms that modulate estrogen metabolism, coagulation, cardiovascular disease and osteoporosis
• Uncovers genetic susceptibility to breast cancer, osteoporosis, thromboses, stroke, atherosclerosis, and heart disease

Estrogen Metabolism

CYP1A1 CYP1B1 COMT (catechol-O-methyl transferase) GST (M1 and P1)

These genes affect how the body breaks down and clears estrogen and its metabolites. The SNPs primarily focus on the cytochrome P450 enzymes that metabolize estrogen and lead to the formation of anti- or procarcinogenic metabolites such as 2-OHE1 and 4-OHE1, respectively. These genes effect the distribution of 2-OH Estrone & 16·-OH Estrone, whose ratio is associated with breast cancer and osteoporosis.

Hyper Coagulation

GP3a (Glycoprotein 3) PAI-1 (Plasminogen activator inhibitor-1)
Factor 2 (prothrombin) Factor 5 (Leiden)

These genetic variants focus on estrogen's interaction with some of the key constituents of the clot formation and fibrinolysis process, such as clotting factors and inhibitors of fibrinolysis. They can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thromboses, heart attacks, and strokes; especially in those women take supplemental estrogens and oral contraceptives.

Cardiovascular

ApoE (apoliprotein E) MTHFR (C677T & G1298T polymorphisms)
TNF-alpha (-308 G-A polymorphism) IL-6 (-174G-C polymorphism)

These genes affect how the body processes cholesterol, responds to inflammation, and metabolizes Bvitamins. The presence of these SNPs can increase risk of cardiovascular disease, and blood vessel damage.

Osteoporosis

VDR (BsmI RFLP) COL1A1(2046 G-T polymorphism)
TNF-alpha (-308 G-A polymorphism) IL-6 (-174G-C polymorphism)

Osteoporosis SNPs relate to estrogen's influence on inflammation, bone resorption, vitamin D, and collagen formation.